Aidea Pharma(SH:688488) Xin Lang Cai Jing·2025-11-07 05:30Core Viewpoint - Eddie Pharmaceuticals experienced a stock price decline of 2.04% on November 7, 2023, with a current price of 14.37 CNY per share and a market capitalization of 6.047 billion CNY [1] Financial Performance - For the period from January to September 2025, Eddie Pharmaceuticals achieved a revenue of 552 million CNY, representing a year-on-year growth of 84.83% [2] - The company reported a net profit attributable to shareholders of -6.8405 million CNY, showing an increase of 88.78% year-on-year [2] Stock and Shareholder Information - As of September 30, 2025, the number of shareholders for Eddie Pharmaceuticals was 12,100, an increase of 1.55% from the previous period [2] - The average circulating shares per shareholder decreased by 1.53% to 34,709 shares [2] - Since its A-share listing, the company has distributed a total of 20.16 million CNY in dividends, with no dividends paid in the last three years [3] Institutional Holdings - As of September 30, 2025, notable institutional shareholders include: - Xingquan Commercial Model Mixed Fund (LOF) A, holding 6.229 million shares, ranked as the fifth largest circulating shareholder and a new entrant [3] - Huatai-PineBridge Healthcare Mixed Fund, holding 4.6607 million shares, ranked seventh and also a new entrant [3] - Penghua Medical Technology Stock A, holding 4.1255 million shares, ranked ninth, with a reduction of 2.68 million shares compared to the previous period [3] - Two funds,招商行业精选股票 and 广发价值核心混合 A, have exited the top ten circulating shareholders list [3] Business Overview - Eddie Pharmaceuticals, established on December 15, 2009, and listed on July 20, 2020, is based in Yangzhou, Jiangsu Province [1] - The company's main business involves the exploration, research, and sales of innovative chemical drugs and human-derived protein products, with revenue composition as follows: - Human-derived protein: 41.11% - New drugs: 35.69% - Diagnostic equipment, reagents, and others: 13.62% - Generic drugs: 9.47% - Others (supplementary): 0.11% [1]